Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

Q4 2024 Earnings Call Transcript March 12, 2025 Harvard Bioscience, Inc. beats earnings expectations. Reported EPS is $0.06, ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Research analysts at Telsey Advisory Group reduced their Q4 2025 earnings per share estimates for Dollar General in a report ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) quickly reached blockbuster status within their ...

Meanwhile, the Claude Code has been an early product but has been an asset for test-driven development, debugging complex ...

Bayer announces fourth-quarter results. NVO cuts cost of Wegovy for the uninsured. ABBV enters obesity space with new deal.

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...